机构：[1]Department of Medicine, Aga Khan University, Karachi, Pakistan[2]GI/Liver Unit, Hospital de Clínicas de Porto Alegre, University of Sao Paulo, Porto Alegre, Brazil[3]Department of Medicine and Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB[4]Division of Gastroenterology, McMaster University Medical Centre, Hamilton, ON, Canada[5]Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院[6]Department of Gastroenterology and Hepatology, Radboud UMC, Nijmegen, The Netherlands[7]Endemic Medicine and Hepatogastroenterology Department, Faculty of Medicine, Cairo University, Cairo, Egypt[8]Gastroenterology and Hepatology Department, Centro Hospitalar Sao Joao, Faculty of Medicine, University of Porto, Porto, Portugal[9]Division of Gastroenterology and Hepatology, University of Iowa Hospitals and Clinics, Iowa City, IA[10]Hepatitis Program, Concord Repatriation General Hospital, University of Sydney, Sydney, NSW, Australia[11]Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK[12]Section of Hepatology, Rush University Medical Center, Chicago, IL[13]Department of Medicine, Division of Hepatology, Faculty of Health Sciences, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa[14]Division of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH[15]Department of Gastroenterology & Hepatology, Koç University Medical School, Istanbul, Turkey.
Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition) in 2018, additional high-quality evidence has emerged with relevance to the diagnosis, staging, and treatment of liver cancer in and outside China that requires the guidelines to be updated. The new edition (2019 Edition) was written by more than 70 experts in the field of liver cancer in China. They reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years. Key Messages: Most importantly, the new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People's Republic of China in December 2019.
第一作者机构：[1]Department of Medicine, Aga Khan University, Karachi, Pakistan
通讯作者：
通讯机构：[15]Department of Gastroenterology & Hepatology, Koç University Medical School, Istanbul, Turkey.[*1]Department of Gastroenterology and Hepatology, Koç University Medical School, Topkapi, Davutpasa Cad. No: 4 34010 Zeytinburnu, Istanbul, Turkey
推荐引用方式(GB/T 7714)：
Saeed Hamid,Mario R. Alvares da Silva,Kelly W. Burak,et al.Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)[J].LIVER CANCER.2020,9(6):682-720.doi:10.1159/000509424.
APA：
Saeed Hamid,Mario R. Alvares da Silva,Kelly W. Burak,Tao Chen,Joost P.H. Drenth...&Cihan Yurdaydin.(2020).Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).LIVER CANCER,9,(6)
MLA：
Saeed Hamid,et al."Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)".LIVER CANCER 9..6(2020):682-720
医学